Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation

Area of Science:

• Hematology
• Transplantation Immunology
• Metabolic Disorders

Background:

• Dyslipidemia is an underrecognized complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT).
• It is associated with factors including endocrine dysfunction, graft-versus-host disease (GVHD), and immunosuppressive therapies.
• Current understanding of molecular pathways and management guidelines for post-HSCT dyslipidemia remains limited.

Purpose of the Study:

• To review the pathogenesis of dyslipidemia after allo-HSCT, with a focus on its relationship with acute and chronic graft-versus-host disease (aGVHD/cGVHD).
• To summarize comprehensive treatment strategies for managing dyslipidemia in patients who have undergone allo-HSCT.

Main Methods:

• Literature review focusing on dyslipidemia post-allo-HSCT.
• Analysis of associations between dyslipidemia, GVHD, and immunosuppressive agents.
• Synthesis of current knowledge on molecular signaling pathways and treatment options.

Main Results:

• Dyslipidemia is multifactorial in allo-HSCT recipients, significantly influenced by GVHD and medications.
• Specific molecular pathways linking GVHD to dyslipidemia require further elucidation.
• Evidence-based guidelines for dyslipidemia management post-HSCT are lacking.

Conclusions:

• Dyslipidemia is a significant post-allo-HSCT complication requiring greater clinical attention.
• Understanding the interplay between GVHD and metabolic changes is crucial for effective management.
• Development of standardized treatment protocols for dyslipidemia after HSCT is needed.